Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Por Guzman, Cristina B., Duvvuru, Suman, Akkari, Anthony, Bhatnagar, Pallav, Battioui, Chakib, Foster, Wendra, Zhang, Xiaotian Michelle, Shankar, Sudha S., Deeg, Mark A., Chalasani, Naga, Hardy, Thomas A., Kazda, Christof M., Pillai, Sreekumar G.
Publicado no Hepatol Commun (2018)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:12...

Por Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Publicado no Diabetes Care (2017)